Monday, November 9, 2026

USD/EUR Falls By 1% In The Last 21 Sessions

USD/EUR Falls By 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.99% for the last 21 sessions. At 13:09 EST on Friday, 21 July, USD/EUR (USDEUR) is $0.90.

USD/EUR's yearly highs and lows, it's 1.319% up from its 52-week low and 14.272% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.14%, a negative 0.09%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.20% (last week), 0.35% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd forex signal: on the cusp of a short-term pullback - 19 July 2023. According to DailyForex on Wednesday, 19 July, "The EUR/USD price was trading at 1.1225, a few pips below this week's high of 1.1275.", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bearish viewSell the EUR/USD pair and set a take-profit at 1.1150."
  • Eur/usd: A push to a 1.15-1.20 range probably requires two things – socgen. According to FXStreet on Wednesday, 19 July, "Economists at Société Générale note two important things needed to propel EUR/USD into a 1.15-1.20 range.", "A push to a 1.15-1.20 EUR/USD range probably requires two things - an improvement in expectations about Eurozone GDP growth and a stronger belief that the ECB will continue hiking rates after the Fed has finished."
  • Eur/usd: room to correct lower before the end of the week – ING. According to FXStreet on Wednesday, 19 July, "For now, they've preferred to keep expectations close to two rate hikes (43 bps) as EUR/USD has held above 1.1200 thanks to the Dollar's still softish momentum.", "We still see room for the overvalued EUR/USD (in the short-term) to correct lower before the end of the week, with a move back to the 1.1150/1.1170 region as a first step."
  • Eur/usd price analysis: trades with a mild negative bias, bullish potential seems intact. According to FXStreet on Wednesday, 19 July, "This is holding back traders from placing bearish bets around the EUR/USD pair and positioning for an extension of the previous day's modest pullback from the 1.1275 region, or the highest level since February 2022.", "The EUR/USD pair struggles to gain any meaningful traction on Wednesday and oscillates in a narrow trading band, above the 1.1200 mark through the Asian session."
  • Eur/usd extends pullback from 1.1280 resistance as ECB vs. fed divergence appears dicey. According to FXStreet on Wednesday, 19 July, "It's worth observing that mixed headlines surrounding China and optimism at the equity markets also tease the EUR/USD bears amid a sluggish session. ", "With this, the EUR/USD is likely to extend the latest pullback amid a light calendar."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com